A Study of Lasmiditan in Healthy Participants

Exclusion Criteria

• •Have known allergies to lasmiditan, related compounds or any components of the formulation.
• •Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study.
• •Show evidence of active renal disease or estimated glomerular filtration rate (eGFR) less than 60 milliliter per minute (mL/min) per 1.73 m².
• •Show evidence of or positive serology for human immunodeficiency virus (HIV) infection, hepatitis B or C.
• •Are women with a positive pregnancy test or women who are lactating.
• •Have a clinically significant abnormality in the neurological examination.
• •Have a history of syncope, presyncopy, uncontrolled vertigo, postural dizziness, or at risk for falls, as judged to be clinically significant by the investigator.
• •Have orthostatic hypotension with or without dizziness and/or syncope at screening or Day -1 upon repeat testing, or a history of it.